FR2924024B1 - Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse - Google Patents

Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse

Info

Publication number
FR2924024B1
FR2924024B1 FR0708296A FR0708296A FR2924024B1 FR 2924024 B1 FR2924024 B1 FR 2924024B1 FR 0708296 A FR0708296 A FR 0708296A FR 0708296 A FR0708296 A FR 0708296A FR 2924024 B1 FR2924024 B1 FR 2924024B1
Authority
FR
France
Prior art keywords
nanoparticles
active ingredients
aqueous solubility
therapeutic active
low aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0708296A
Other languages
English (en)
French (fr)
Other versions
FR2924024A1 (fr
Inventor
Patrick Couvreur
Harivardhan Reddy Lakkireddy
Franco Dosio
Barbara Stella
Luigi Cattel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Paris Sud
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Paris Sud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0708296A priority Critical patent/FR2924024B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Paris Sud filed Critical Centre National de la Recherche Scientifique CNRS
Priority to CA2706933A priority patent/CA2706933C/fr
Priority to US12/744,424 priority patent/US8962552B2/en
Priority to EP08856747.4A priority patent/EP2219678B1/fr
Priority to CN200880125358XA priority patent/CN101925365B/zh
Priority to JP2010535434A priority patent/JP5520228B2/ja
Priority to PCT/FR2008/052147 priority patent/WO2009071850A2/fr
Publication of FR2924024A1 publication Critical patent/FR2924024A1/fr
Application granted granted Critical
Publication of FR2924024B1 publication Critical patent/FR2924024B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
FR0708296A 2007-11-27 2007-11-27 Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse Active FR2924024B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0708296A FR2924024B1 (fr) 2007-11-27 2007-11-27 Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
US12/744,424 US8962552B2 (en) 2007-11-27 2008-11-27 Nanoparticles of therapeutic agents having low water solubility
EP08856747.4A EP2219678B1 (fr) 2007-11-27 2008-11-27 Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
CN200880125358XA CN101925365B (zh) 2007-11-27 2008-11-27 具有低水溶解度的治疗性活性物质的纳米颗粒
CA2706933A CA2706933C (fr) 2007-11-27 2008-11-27 Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
JP2010535434A JP5520228B2 (ja) 2007-11-27 2008-11-27 水溶解度の低い治療剤のナノ粒子
PCT/FR2008/052147 WO2009071850A2 (fr) 2007-11-27 2008-11-27 Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0708296A FR2924024B1 (fr) 2007-11-27 2007-11-27 Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse

Publications (2)

Publication Number Publication Date
FR2924024A1 FR2924024A1 (fr) 2009-05-29
FR2924024B1 true FR2924024B1 (fr) 2012-08-17

Family

ID=39521786

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0708296A Active FR2924024B1 (fr) 2007-11-27 2007-11-27 Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse

Country Status (7)

Country Link
US (1) US8962552B2 (https=)
EP (1) EP2219678B1 (https=)
JP (1) JP5520228B2 (https=)
CN (1) CN101925365B (https=)
CA (1) CA2706933C (https=)
FR (1) FR2924024B1 (https=)
WO (1) WO2009071850A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2937537A1 (fr) 2008-10-29 2010-04-30 Centre Nat Rech Scient Nanoparticules de statine
US9517476B2 (en) * 2008-10-31 2016-12-13 Hitachi Koki Co., Ltd. Centrifuge with acceleration and deceleration time display
WO2010063080A1 (en) 2008-12-05 2010-06-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
FR2988092B1 (fr) 2012-03-16 2014-04-25 Centre Nat Rech Scient Complexes de vitamine c, nanoparticules desdits complexes, procedes pour leur preparation, leurs compositions, leurs utilisations cosmetiques et procede de traitement cosmetique
EP2846773A4 (en) 2012-05-10 2015-12-30 Painreform Ltd DEPOT FORMULATIONS OF A LOCAL ANESTHETICS AND METHOD FOR THE MANUFACTURE THEREOF
CN103421085B (zh) * 2012-05-18 2015-07-29 中国科学院上海药物研究所 用于增加紫杉醇或以紫杉醇结构为基础的类似药物的溶解度的寡肽
CN103351424B (zh) * 2013-06-09 2016-05-04 东南大学 一种紫杉醇或多烯紫杉醇奥曲肽偶联物的制备方法
DK3204413T3 (da) * 2014-10-06 2019-12-09 Mayo Found Medical Education & Res Bærerantistofsammensætninger og fremgangsmåder til fremstilling og anvendelse heraf
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
SG11201802832UA (en) 2015-10-07 2018-05-30 Sumitomo Dainippon Pharma Co Ltd Pyrimidine compound
CA3107409A1 (en) 2018-07-23 2020-01-30 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
EP3598982A1 (en) * 2018-07-23 2020-01-29 Centre National De La Recherche Scientifique Bioconjugates of neuropeptides derivatives
FR3110427B1 (fr) 2020-05-20 2023-07-14 Laboratoires Eriger Conjugué terpenique de couplage
JP2025535561A (ja) * 2022-12-19 2025-10-24 元樟生物科技股▲フン▼有限公司 薬物リンカーおよびリンカー共役化合物
CN119613473B (zh) * 2024-12-06 2026-02-27 大连医科大学 阿霉素-角鲨烯小分子前药及其制备方法和应用
CN120210296A (zh) * 2025-03-27 2025-06-27 安徽天寅生物技术有限公司 一种纳米级水溶性角鲨烯的制备工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02204489A (ja) * 1989-02-02 1990-08-14 Ajinomoto Co Inc 易溶性２’，３’―ジデオキシイノシン、その製造法及び２’，３’―ジデオキシイノシン水性溶液の製造法
US5489589A (en) * 1994-12-07 1996-02-06 Bristol-Myers Squibb Company Amino acid derivatives of paclitaxel
GB9718791D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Medicaments
CA2684454A1 (en) * 1999-05-21 2000-11-18 American Bioscience, Llc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
EP1498120A1 (en) 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
US20050100577A1 (en) * 2003-11-10 2005-05-12 Parker Theodore L. Expandable medical device with beneficial agent matrix formed by a multi solvent system
FR2874016B1 (fr) * 2004-06-30 2006-11-24 Centre Nat Rech Scient Cnrse Nanoparticules de derives de la gemcitabine
US20060198940A1 (en) * 2005-03-04 2006-09-07 Mcmorrow David Method of producing particles utilizing a vibrating mesh nebulizer for coating a medical appliance, a system for producing particles, and a medical appliance

Also Published As

Publication number Publication date
FR2924024A1 (fr) 2009-05-29
WO2009071850A2 (fr) 2009-06-11
EP2219678A2 (fr) 2010-08-25
CN101925365B (zh) 2013-03-06
US8962552B2 (en) 2015-02-24
WO2009071850A3 (fr) 2009-11-26
WO2009071850A8 (fr) 2009-09-17
CA2706933A1 (fr) 2009-06-11
CN101925365A (zh) 2010-12-22
US20100305030A1 (en) 2010-12-02
JP5520228B2 (ja) 2014-06-11
EP2219678B1 (fr) 2021-05-19
JP2011506276A (ja) 2011-03-03
CA2706933C (fr) 2016-07-05

Similar Documents

Publication Publication Date Title
FR2924024B1 (fr) Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
IL243534A0 (en) Methods for the preparation of biologically active compounds in nanoparticulate form
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
FR2892923B1 (fr) Utilisatiion des derives de l'acide para-coumarique ou para- hydroxycinnamique dans des compositions cosmetiques ou dermatologiques.
ZA201005665B (en) Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents
EP2012751A4 (en) NEW NANOPARTICLES FOR THE ACTIVE COMPOSITION
EP1730163A4 (en) Pharmaceutical salts of 3-O- (3,3-dimethylsuccinyl) betulinic acid
JP2009280627A5 (https=)
BRPI0920515A2 (pt) Métodos para produzir nanopartículas de polímero e formulações de ingredientes ativos
ZA200902632B (en) Haloalkylsufonanilide derivative or salt thereof, herbicide comprising the derivative as active ingredient, and use of the herbicide
EA201290498A1 (ru) Терапевтические полимерные наночастицы, включающие эпотилон, и способы их получения и применения
IL206443A0 (en) Polysaccharide derivatives of lipoic acid, their preparation, use as skin cosmetics and medical devices
EP2046290A4 (en) AQUEOUS DRONABINOL FORMULATIONS
EP2612914A4 (en) OLIGONUCLEOTIDE AND THERAPEUTIC AGENT AGAINST DYSLIPIDEMIA WITH THE OLIGONUCLEOTIDE AS AN ACTIVE SUBSTANCE
BRPI0907624A2 (pt) tratamento e prevenção de doenças cardíacas usando duas ou mais isoformas do fator de crescimento de hepatócito
EP2582424A4 (en) DISTRIBUTION OF SKIN CARE PRODUCTS
PL1909843T3 (pl) Przeciwnowotworowe biokoniugaty kwasu hialuronowego lub jego pochodne otrzymane przez pośrednie sprzęganie chemiczne i ich zastosowanie w dziedzinie farmacji
EP2307056A4 (en) STABILIZED AQUEOUS FORMULATION WITH PARACETAMOL
EP2043623A4 (en) NANOPARTICLE FORMULATIONS OF MODAFINIL
PL2298071T3 (pl) Wodny roztwór do konserwacji tkanek i narządów
EP2512458A4 (en) SYSTEM FOR DELIVERING A TOPIC ACTIVE MEDICINE OF LOW TOXICITY
FR2937549B1 (fr) Nanoparticules de derives beta-lactamine
FR2926081B1 (fr) Derives d'acide hydroxy-bisphosphonique comme vecteur ciblant le tissu osseux
ZA201202174B (en) Dicyclanil-based aqueous suspension and non-aqueous solution pour-on and spray on formulations for the prevention and treatment of insect infestation in animal
EP2377865A4 (en) CYCLOBUTYLPURINE DERIVATIVES, ANGIOGENESIS-SUPPORTING AGENT, LUMENIZING-PROMOTING AGENT, NEUROCYTE GROWTH-PROMOTING AGENT AND MEDICAMENT

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19